Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Patients and methods: Patients had a maximum of three prior chemotherapy lines with no more than two prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Pecorelli, S., Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaròs, D., Lhommé, C., Lissoni, A. A., Vermorken, J. B., du Bois, A., Poveda, A., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., Guastalla, J. P.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844948/
https://www.ncbi.nlm.nih.gov/pubmed/19906760
http://dx.doi.org/10.1093/annonc/mdp514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844948/
https://www.ncbi.nlm.nih.gov/pubmed/19906760
http://dx.doi.org/10.1093/annonc/mdp514

Ejemplares similares